Effect of pulmonary surfactant combined with lung protective ventilation strategy on treatment of neonatal severe meconium aspiration syndrome complicated with acute lung injury
10.7619/jcmp.201721006
- VernacularTitle:肺表面活性物质联合肺保护通气策略治疗新生儿重型胎粪吸入综合征合并急性肺损伤的疗效观察
- Author:
Huifen JIANG
1
;
Yong ZHAO
;
Jinxiu WANG
Author Information
1. 南京医科大学附属常州妇幼保健院新生儿科
- Keywords:
pulmonary surfactant;
protective ventilation;
severe meconium aspiration syndrome;
acute lung injury
- From:
Journal of Clinical Medicine in Practice
2017;21(21):22-24
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of pulmonary surfactant combined with lung protective ventilation strategy on treatment of neonatal severe meconium aspiration syndrome (MAS) complicated with acute lung injury.Methods A total of 50 neonates with severe MAS complicated with acute lung injury were randomly divided into treatment group and control group,with 25 cases in each group.The treatment group were treated with pulmonary surfactant combined with lung protective ventilation strategy,while the control group were only treated with lung protective ventilation strategy.The ventilator associated indexes,oxygenation index,lung compliance indexes,ventilation time and length of hospital stay of the two groups were recorded.Results ① The inhaled oxygen concentration of treatment group decreased significantly within 24 hours,arterial partial pressure of oxygen increased significantly,the mean airway pressure decreased rapidly within 24 hours,and there were significant differences at different time points (P ＜ 0.05).② The oxygenation index of treatment group was lower than that of the control group.The lung compliance of treatment group was higher than that of the control group.③ The ventilation time and hospital stay of the treatment group were shorter than that of the control group.Conclusion The curative effect of pulmonary surfactant combined with lung protective ventilation strategy is better than lung protective ventilation strategy alone in the treatment of neonatal severe MAS with acute lung injury.
